IDH1 and glioblastoma: We recently showed how the simultaneous targeting of the glycolysis and the glutaminolysis pathways can significantly improve progression free and overall survival in orthotopic syngeneic GBM mouse models and in a long-term survival patient with an IDH1(R132H)-mutant GBM [123,213].